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Immunologists and parasitologists have detected differences
between individuals in developed and so-called developing
countries in respect of the manner in which the immune
system reacts to antigens. This should be of particular interest
to health professionals in Africa, where immunisation has been
described as ‘the greatest public health gift we can offer
children’.1 Research-wise, variation in the post-vaccination
immune response could well make the results of vaccine trials
extremely difficult to interpret correctly. What is important
from a practical point of view is that vaccine efficacy in
developing countries may frequently be compromised, for
reasons given below.
For instance, deficiency of zinc in the diet is widespread in
underdeveloped regions, where it is responsible for a defective
T-helper cell type 1 (Th1) response,2 because of decreased
production of interferon-gamma and interleukin-2. Perhaps
better known is the theory that reduced exposure to infectious
diseases in developed countries in modern times has, because
of resultant changes in immune function, led to an increased
prevalence of atopy compared with that in developing parts of
the world, where exposure to various bacterial and viral
pathogens is greater.3 Important qualitative and quantitative
differences between Africans and non-Africans in relation to T-
cell cytokine production have been reported.4,5 Furthermore,
host genetic differences can be a source of variation in cytokine
levels within the same population.6 This lack of uniformity
could be of significance for immune intervention strategies and
relevant to the design of vaccines. Whereas the response to
vaccines in developing and developed countries may differ, it
must be emphasised that factors such as those mentioned
above have not yet actually been shown to affect vaccine
efficacy. On theoretical immunological grounds, however, it
would seem that they might do so by downregulation of the
immune reaction, something that is not widely appreciated;
and cognisance should be taken of this probability.
Crohn’s disease, which characteristically occurs in
industrialised societies, serves as another example of how the
nature of the immune response can apparently depend upon
whether people live in an economically developed country or
in a Third-World country. The pathogenesis of this
inflammatory bowel condition is currently thought to involve
over-reaction of the immune system to an unknown
environmental agent(s). A predisposing genetic factor may be
involved. It has been suggested that a reason why Crohn’s
disease is rare in tropical areas with poor sanitation is that the
Th2 gut mucosal response provoked by the parasitic worms
which are ubiquitous in such areas leads to modulation of
immune reactions to other stimuli.7,8 Similarly, there is evidence
that enteric helminthiasis affects the gastric inflammatory
response in Helicobacter pylori infection, which may partly
explain the contrasting immune reactions and differing
patterns of progression of this disease in the developed and
developing worlds.9,10 Of course, Crohn’s disease and H. pylori
infection are by no means the most important public health
problems in developing countries. They merely serve to
illustrate how one condition might influence the
immunological response to another or to a vaccine.
It is not yet common knowledge that Th2-orientated immune
activation in chronic helminthiasis results in a diminished
response to certain kinds of vaccines against several diseases.
These include cholera, diphtheria, tetanus and tuberculosis.11
The same may apply to particular types of HIV/AIDS and
antimalarial vaccines.12,13 The immune mechanisms that lead to
protection after vaccination determine vaccine efficacy in
individuals who are Th2-polarised before vaccination. These
mechanisms differ and it is not always clear what they are for
any given vaccine. In the case of oral vaccines, local mucosal
changes caused by the presence of worms in the gut might play
a role in reducing vaccine efficacy. Anthelminthic treatment
before vaccination has been shown to enhance the post-
immunisation response to vaccines against more than one
bacterial disease.14,15
To at least some extent, these phenomena may explain why
vaccines often elicit poor immune reactions in people living in
developing regions, although the reasons are likely to be
multifactorial. They have not yet been clarified to the extent
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that they have influenced vaccine design — yet it is logical that
before new vaccines, for example against tuberculosis, can
rationally be developed, it is necessary to understand why the
bacille Calmette-Guérin (BCG) vaccine has failed in certain
situations.16 It is important that differences in the immune
response caused by variables such those indicated above, be
taken into account when planning research on vaccines. This
also applies to interpreting the findings of vaccine trials,
especially when results from subjects in a developed country
are compared with those for individuals in a poor country on
another continent. Otherwise, erroneous conclusions regarding
the potential effectiveness of vaccines could easily be reached.
Disadvantaged children in poor countries derive great
benefit from immunisation against various diseases and
vaccination remains ‘the greatest public health gift we can offer
children’.1 Anthelminthic interventions also have positive
health benefits in communities where the prevalence of
intestinal helminthiasis is high. Consideration now needs to be
given to whether immunisation against non-helminthic
diseases and deworming should sometimes go hand in hand,
but with the possible negative consequences of deworming on
the prevalence of allergic and other conditions being taken into
account.17-21
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